ARTICLE | Company News
Apeiron Biologics, GlaxoSmithKline deal
February 8, 2010 8:00 AM UTC
Apeiron granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize APN01. The recombinant human angiotensin-converting enzyme 2 (ACE2) is in Phase I testing to treat acute resp...